FDA sends warning letter after Chinese supplier breaks GLP-1 import restrictions

FDA Issues Warning to Chinese Supplier Over GLP-1 API Relabeling

The FDA issued a warning letter to Chinese manufacturer Harbin Jixianglong Biotech for allegedly circumventing import restrictions on GLP-1 receptor agonist active pharmaceutical ingredients (APIs). In September 2025, the FDA established a "green list" of approved facilities to prevent unverified foreign sources from entering the U.S. Jixianglong, despite being on this list, was found to have purchased semaglutide API from an unapproved facility, relabeling it as its own. This action was deemed an attempt to bypass safeguards and posed a risk to consumers. Following FDA's concerns and recommendations, Jixianglong eventually recalled the affected semaglutide batches from the U.S. market in February, citing failures in process and bacterial endotoxin method validation.

• The FDA implemented new restrictions in September 2025, creating a "green list" of authorized facilities to import GLP-1 APIs into the U.S., aiming to protect patients from potentially dangerous ingredients. Harbin Jixianglong Biotech, initially added to this list, was found to have violated these safeguards. FDA inspectors discovered the company purchased semaglutide, the active ingredient in Ozempic and Wegovy, from an unapproved facility and then relabeled it as manufactured at its own green-listed plant, attempting to circumvent the established import alert.
• Upon inspection, Jixianglong initially cited high demand for semaglutide API in the U.S. as a reason for occasionally purchasing products externally for resale. The company acknowledged lacking appropriate procedures for releasing externally purchased products and proper batch records for repackaging and labeling. While committing to cease the sale of externally procured products, Jixianglong initially failed to adequately address the FDA's concerns regarding the batches already distributed in the U.S. market.
• Following the FDA's recommendation, Harbin Jixianglong Biotech eventually recalled the affected semaglutide API batches from the U.S. market in February. The FDA's March 11 enforcement report listed these recalls for "semaglutide, for Rx compounding use only." The official reasons for the recalls were attributed to "failing to complete process validation and bacterial endotoxin method validation before distribution," highlighting significant quality control deficiencies in the relabeled products.

Semaglutide's Impact on the Evolving GLP-1 Treatment Landscape

The type 2 diabetes treatment landscape has undergone a dramatic shift over the past five years, marked by the rapid adoption of newer therapeutic classes and a fundamental change in prescribing patterns. From January 2022 to May 2023, first-line use of GLP-1 receptor agonists surged from 6% to 18%, while SGLT2 inhibitors increased from 4% to 7%. This represents a significant departure from historical patterns where metformin dominated first-line therapy at 74-83%. Concurrently, traditional agents experienced decline, with first-line metformin use dropping from 76% to 64%, sulfonylureas falling from 4% to 2%, and DPP-4 inhibitors decreasing from 2% to 1%. The patient demographics receiving these newer therapies have also evolved, with first-line GLP-1RA users in 2022-2023 being younger, predominantly female, more likely to have Medicaid coverage, and presenting with fewer comorbidities compared to earlier adopters.

Network meta-analyses from 2024 have provided robust evidence supporting the clinical superiority of these newer agents across multiple endpoints. GLP-1 receptor agonists demonstrate significant reductions in major adverse cardiovascular events (RR 0.83, 95% CI 0.71-0.97) and substantial weight reduction (MD -3.87 kg, 95% CI -5.54 to -2.21) in adults aged ≥65 years. SGLT2 inhibitors have established themselves as the preferred choice for patients with cardiovascular and renal comorbidities, preventing hospitalization for heart failure (RR 0.66, 95% CI 0.57-0.77), reducing composite renal outcomes (RR 0.69, 95% CI 0.53-0.89), and providing modest weight benefits. Notably, combination therapy with metformin and SGLT2 inhibitors has shown significantly reduced risks of all-cause mortality (aHR 0.74, 95% CI 0.64-0.84) and composite kidney outcomes compared to SGLT2 inhibitor monotherapy.

Current treatment guidelines reflect this evidence-based evolution, with 2026 recommendations maintaining metformin as first-line therapy while positioning empagliflozin 10 mg as second-line treatment across multiple pathways, followed by tirzepatide, semaglutide, liraglutide, or dulaglutide as third-line options. The approval of entirely novel drug classes, including glucokinase activators (dorzagliatin in China) and imeglimin (in Japan), further expands the therapeutic arsenal. Expert consensus has coalesced around a "treat-to-benefit" approach, emphasizing early combination therapy with agents providing proven cardiovascular benefits rather than traditional stepwise intensification. This paradigm shift is supported by Danish utilization data from 2021 showing that while metformin remains the most prescribed agent at 39% of consumption, SGLT2 inhibitors and GLP-1 receptor agonists now comprise 17% and 16% respectively, with substantially increased treatment complexity as 44% of patients now use combination therapy compared to historical patterns.

Upholding Patient Safety: The Critical Role of Verified Semaglutide APIs

Published safety data from 2022-2026 demonstrates that semaglutide maintains a generally favorable safety profile across its approved indications of type 2 diabetes and obesity management. However, recent surveillance data has identified new safety signals requiring careful monitoring, while gastrointestinal adverse events remain the most common tolerability concern.

• Gastrointestinal tolerability: Meta-analyses consistently show nausea (20-24% vs 8% placebo) and diarrhea (11-13% vs 2% placebo) as the most frequent adverse events, with gastrointestinal disorders representing the primary cause of treatment discontinuation in 12-15% of patients

• Cardiovascular benefits: Large-scale meta-analysis of 19,717 participants demonstrated significant reductions in major adverse cardiovascular events (RR 0.82), cardiovascular death (RR 0.81), and need for coronary revascularization (RR 0.74), supporting cardiovascular safety across high-risk populations

• Emerging psychiatric safety signals: Recent FAERS database analysis revealed disproportionate reporting of psychiatric adverse events, including anxiety (PRR 1.34), depression (PRR 1.83), and suicidal ideation (PRR 3.44), prompting enhanced surveillance requirements

• Ophthalmologic concerns: Vision-related adverse events show mixed findings, with increased diabetic retinopathy complications in SUSTAIN-6 but recent association with non-arteritic anterior ischemic optic neuropathy (NAION) requiring further investigation (OR 3.92)

• New adverse event signals: 2024 FAERS analysis identified previously unrecognized serious events including pancreatic failure (ROR 36.34), hepatic pain (ROR 4.20), and hemorrhagic diarrhea (ROR 3.69), leading to FDA black box warning implementation

• Real-world safety profile: Clinical practice data from 1,403 patients showed ADR incidence of 1.85% with mean HbA1c reduction of 10.8 mmol/mol, though this represents potential underreporting compared to actual adverse event rates in routine care

Navigating Supply Chain Challenges for GLP-1 Therapies

Current treatment approaches for type 2 diabetes and obesity face significant barriers that limit therapeutic success and patient outcomes. These challenges span from inadequate treatment efficacy and safety concerns to complex patient management issues and healthcare system limitations.

• Treatment inadequacy and side effects: Despite improvements in therapy and development of new drugs, treatment remains insufficient primarily due to associated side effects of most available medications, while gastrointestinal adverse events occur more frequently with newer agents like tirzepatide

• Glycemic control standardization: The most important unresolved issue is establishing a safe glycosylated hemoglobin A1c value that balances benefits and side effects, complicated by different guidelines suggesting varying A1c targets, generating confusion for patients and clinicians

• Delayed insulin initiation and poor technique: Insulin therapy is typically initiated after a mean diabetes duration of 8.80 ± 6.42 years, indicating problematic delays, while inadequate knowledge regarding insulin usage influences acceptance, adherence, and treatment outcomes

• Injection-related complications: The prevalence of lipohypertrophy reaches 12.57% and is significantly associated with incorrect injection techniques including improper injection angle, site selection, rotation practices, and needle reuse

• Complex dietary interventions: Typical nutrition-focused interventions are burdensome due to complex instructions requiring complete dietary changes, while adults with persistent hyperglycemia often have low health literacy levels that create barriers to adherence

• Progressive beta-cell dysfunction: Beta-cell dysfunction is present at T2DM diagnosis and progressively worsens with disease duration, leading to treatment failure, while regenerative capacity appears limited in humans, making preservation strategies critical

• Diagnostic gaps and persistent hyperglycemia: One-third of Americans with type 2 diabetes remain undiagnosed and at high risk for complications, while more than 15% of US adults with diagnosed T2DM have persistent hyperglycemia with elevated risks for amputation and cardiovascular mortality

Safeguarding the GLP-1 Supply: A Critical Wake-Up Call

The recent FDA warning letter and subsequent recall involving a Chinese manufacturer's semaglutide API sends a stark reminder about the fragility of the global pharmaceutical supply chain and the paramount importance of product integrity. Semaglutide, a leading GLP-1 receptor agonist, has revolutionized the management of type 2 diabetes and obesity, offering significant benefits in glycemic control, weight reduction, and even cardio-renal protection. Its widespread adoption, however, has also created a unique set of challenges, particularly concerning its active pharmaceutical ingredient (API) sourcing.

This incident highlights a critical risk: the deliberate circumvention of regulatory safeguards, even by facilities ostensibly on an "approved" list. The discovery of bacterial endotoxin and failures in process validation in the recalled batches underscores the immediate and severe patient safety implications. Substandard or falsified products can lead to unpredictable clinical outcomes, ranging from lack of efficacy to serious adverse events, potentially exacerbating known risks associated with GLP-1 RAs such as gastrointestinal issues, or even emerging signals like diabetic retinopathy and Nonarteritic Anterior Ischemic Optic Neuropathy.

The immense demand for semaglutide, fueled in part by its off-label use for weight loss and amplified by social media, has unfortunately created a fertile ground for an unregulated market. Studies have already revealed the prevalence of falsified products sold online, often containing incorrect active ingredient levels, low purity, and dangerous contaminants. This event will undoubtedly prompt heightened scrutiny from regulatory bodies, leading to more stringent oversight of API manufacturing and import processes. For pharmaceutical companies, it reinforces the imperative for robust supply chain diligence and transparency. Ultimately, ensuring patient safety and maintaining trust in these vital medications requires a collective effort from regulators, manufacturers, healthcare providers, and patients to champion legitimate supply channels and remain vigilant against the pervasive threat of substandard products.